- Home
- Publications
- Publication Search
- Publication Details
Title
Atezolizumab for the treatment of breast cancer
Authors
Keywords
-
Journal
Expert Review of Anticancer Therapy
Volume -, Issue -, Pages 1-8
Publisher
Informa UK Limited
Online
2020-02-18
DOI
10.1080/14737140.2020.1732211
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
- (2019) Oscar M. Rueda et al. NATURE
- Immunotherapy and targeted therapy combinations in metastatic breast cancer
- (2019) Francisco J Esteva et al. LANCET ONCOLOGY
- Checkpoint Blockade Strategies in the Treatment of Breast Cancer: Where We Are and Where We Are Heading
- (2019) Jeremy Force et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
- (2018) D A Yardley et al. ANNALS OF ONCOLOGY
- Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
- (2018) Hope S. Rugo et al. CLINICAL CANCER RESEARCH
- Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort
- (2018) Elisa Gobbini et al. EUROPEAN JOURNAL OF CANCER
- Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
- (2018) Andrew Tutt et al. NATURE MEDICINE
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
- (2016) Wendie D. den Brok et al. BREAST CANCER RESEARCH AND TREATMENT
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor
- (2016) Rong Deng et al. mAbs
- A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors
- (2016) Samit Chatterjee et al. Oncotarget
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients
- (2013) D. W. Miles et al. ANNALS OF ONCOLOGY
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
- (2011) R. D. Schreiber et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now